Ethno-epidemiology of HCV, HIV and Overdose associated with Drug Markets and Drug Tourism

《多样性摘要》副刊 拟议的多样性补编旨在通过以下方式促进科学界的多样性 对拉丁裔临床心理学家Samantha Schiavon，M.A.的培训，她有指导药物使用的经验 针对弱势群体和种族/少数民族人群的精神障碍治疗研究。Schiavon女士已经 通过她的医学/临床心理学博士前培训获得了坚实的研究背景 阿拉巴马大学伯明翰分校的博士课程，并将继续推进她的研究 作为加州大学圣地亚哥分校(UCSD)博士后研究员的能力。通过这件事 在补充资料中，Schiavon女士将通过研究耻辱对 注射吸毒者开始用药治疗阿片使用障碍(MOUD)的动机 (PWID)在墨西哥和美国，她将在Steffanie Strathdee博士(初级)的指导下接受培训 Mentor和PI on Parent Grant)，专注于艾滋病毒的世界著名传染病流行病学家 发展中国家的预防研究，托马斯·帕特森博士(共同导师)，以其艾滋病毒/艾滋病而闻名 墨西哥-美国边境地区的预防干预，以及拉勒米·史密斯博士(共同导师)， PWID中的污名研究。通过二次数据分析，本附录将扩展到以下目标 为确定墨西哥和美国的跨文化差异而设立的家长基金 在PWID中使用障碍污名作为Moud治疗启动意向的潜在障碍。具体的 目的是：1)审查主要居住国(墨西哥诉美国)作为预期之间的调解人 物质使用障碍、污名和启动Moud治疗的意图；2)评估 预期的Moud治疗(即丁丙诺啡/亚博酮与美沙酮相比)按原发国家分列的耻辱 居住(墨西哥诉美国)；以及3)审查预期的穆德污名作为国家之间的调解人 主要居住地(墨西哥诉美国)和穆德治疗开始意向。这些结果将告知 开发文化响应性干预措施，以减少耻辱作为Moud治疗启动的障碍 并将作为Schiavon女士未来K23提案的基础。因此，本补充文件不会 仅提供关键支持，以加强Schiavon女士在整个博士后研究期间的培训 UCSD，但也将促进她通过K23过渡到独立临床研究人员 该奖项的重点是减少国际PWID患者开始接受Moud治疗的障碍。

Abstract of Diversity Supplement The proposed Diversity Supplement is designed to promote diversity in the scientific community through the training of Samantha Schiavon, M.A., a Latinx clinical psychologist with experience conducting substance use disorder treatment research among vulnerable and racial/ethnic minority populations. Ms. Schiavon has obtained a strong research background through her pre-doctoral training in the Medical/Clinical Psychology Doctoral Program at the University of Alabama at Birmingham and will continue to advance her research competencies as a research postdoctoral fellow at the University of California San Diego (UCSD). Through this supplement, Ms. Schiavon will build her research capacities through examining the impact of stigma on motivations to initiate medication for opioid use disorder (MOUD) treatment among persons who inject drugs (PWID) within Mexico and the U.S. She will train under the mentorship of Dr. Steffanie Strathdee (primary mentor and PI on parent grant), a world-renowned infectious disease epidemiologist focused on HIV prevention research in developing countries, Dr. Thomas Patterson (co-mentor), known for his HIV/AIDS prevention interventions along the Mexico-U.S. border region, and Dr. Laramie Smith (co-mentor), an expert in stigma research among PWID. Through secondary data analysis, this supplement will expand upon the aims of the parent grant to identify cross-cultural differences between Mexico and the U.S. in MOUD and substance use disorder stigma as potential barriers to MOUD treatment initiation intentions among PWID. The specific aims are to: 1) to examine country of primary residence (Mexico v. US) as a moderator between anticipated substance use disorder stigma and intentions to initiate MOUD treatment; 2) to assess differences in anticipated MOUD treatment (i.e., buprenorphine/suboxone vs. methadone) stigma by country of primary residence (Mexico v. US); and 3) to examine anticipated MOUD stigma as a mediator between country of primary residence (Mexico v. US) and MOUD treatment initiation intentions. These results will inform the development of culturally responsive interventions to reduce stigma as a barrier to MOUD treatment initiation and will serve as the foundation for Ms. Schiavon’s future K23 proposal. Therefore, this supplement will not only provide crucial support to enhance Ms. Schiavon’s training throughout her postdoctoral fellowship at UCSD, but will also facilitate her transition to becoming an independent clinical researcher through a K23 award focused on reducing barriers to MOUD treatment initiation among international populations of PWID.